Professor of Medicine, University Texas MD Anderson Cancer Center, Houston
Hematology
Dr. Richard E. Champlin, MD
|
|
Give Review
Dr. Richard E. Champlin is an expert in the field of Hematology. He attended University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine He over the years received 3 awards: "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Richard E. Champlin has written publications. He has 101 publications published with PubMed. The lastest publication is: 'Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.' Richard Champlin accepts all Medicare patients.
Publications
- Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
- Autologous hematopoietic stem Cell transplantation in light chain amyloidosis (AL) with renal involvement.
- Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.
- Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.
- Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
- Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen:...
- Improvement in clinical outcome of FLT3 ITD mutated Acute myeloid leukemia patients over the last one and a half decade.
- Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
- Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
- The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
- Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation.
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning.
- Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.
- Are changes in HLA Ags responsible for Leukemia relapse after HLA-matched allogeneic hematopoietic SCT?
- High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.
- Enforced fucosylation of cord blood hematopoietic Cells accelerates neutrophil and platelet engraftment after transplantation.
- Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk Myeloma.
- Increased Incidence of Fractures in Recipients of Hematopoietic Stem-Cell Transplantation.
- Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML Cells: enhancement of cytotoxicity with epigenetic modu...
- Patients with mantle Cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
- Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem Cell transplantation for relapsed myeloma.
- Targeting Bruton's tyrosine kinase with ibrutinib in B-Cell malignancies.
- Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hemato...
- Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-Cell-depleted or unmodified allografts.
- Can a Female Donor for a Male Recipient Decrease Relapse Rate for Patients with AML Treated with Allogeneic Hematopoietic Stem Cell Transplantation?
- Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation.
- Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications-Positive Acute Myeloid Leuk...
- Vaccination guidelines after hematopoietic stem Cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice.
- Activating and propagating polyclonal gamma delta T Cells with broad specificity for malignancies.
- Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unre...
- Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy.
- Regulatory B Cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.
- Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
- Short-term cardiac toxicity of autologous hematopoietic stem Cell transplant for multiple myeloma.
- Bioengineering T Cells to target carbohydrate to treat opportunistic fungal infection.
- Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation.
- Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective Analysis with 14-year follow-up.
- Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines of the American Society for Blood and Marrow...
- Letermovir for cytomegalovirus prophylaxis in hematopoietic-Cell transplantation.
- Is there an expiration date for a cord blood unit in storage?
- An Immunodeficiency Scoring Index to predict poor outcomes in hematopoietic Cell transplant recipients with respiratory syncytial virus infections.
- Increasing Chimerism Following Allogeneic Stem Cell Transplantation is Associated with Longer Survival Time.
- Complement component C3 mediates Th1/Th17 polarization in human T-Cell activation and cutaneous GVHD.
- The histone deacetylase inhibitor SAHA sensitizes Acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
- The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.
- The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
- Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome.
- Allogeneic stem cell transplantation as initial salvage for patients with Acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
- Respiratory Syncytial Virus Infections in Children With Cancer.
- Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic Anemia.
- Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood enGraftment.
- Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to...
- Cytarabine, Ki-67, and SOX11 in patients with mantle Cell lymphoma receiving rituximab-containing autologous stem Cell transplantation during first remission.
- Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor Cell mobilization.
- Toward eliminating HLA class I expression to generate universal Cells from allogeneic donors.
- Outcomes in patients with relapsed or refractory Acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
- Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
- A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients w...
- Mechanistic studies on the synergistic cytotoxicity of the nucleoside Analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implic...
- Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem Cell transplantation.
- Multiple mismatches at the low expression HLA loci DP, DQ, DRB3/4/5 associate with adverse outcomes in hematopoietic stem Cell transplantation.
- Outcomes of adults with Acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT).
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed Acute lymphocytic leukemia.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large Cell, follicular and transformed lymphoma: a phase II clinical trial.
- Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem Cell transplant recipients with respiratory syncytial virus infections.
- Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials.
- Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience.
- High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
- Ex Vivo T Cell Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission.
- Clinical application of sleeping beauty and artificial antigen presenting Cells to genetically modify T Cells from peripheral and umbilical cord blood.
- Sleeping beauty system to redirect T-Cell specificity for human applications.
- Hematopoietic Cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative.
- Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
- Incidence and natural history of pure red Cell aplasia in major ABO-mismatched haematopoietic Cell transplantation.
- Bispecific T-Cells Expressing Polyclonal Repertoire of Endogenous ?? T-Cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor.
- Cord-blood engraftment with ex vivo mesenchymal-Cell coculture.
- Dose intensification of Busulfan in the preparative regimen is associated with improved survival: A Phase I/II Controlled, Randomized Study.
- Allogeneic hematopoietic stem Cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study.
- Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome.
- High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-Cell transplantation in patients with refractory lymphoid malignancies.
- Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with Acute lymphoblastic leukemia.
- Bayesian continual reassessment method for dose-finding trials infusing T Cells with limited sample size.
- Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transpla...
- Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission.
- Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation.
- An Adaptive Randomized Trial of Intermittent Dosing Schedule of Aerosolized Ribavirin in Cancer Patients with Respiratory Syncytial Virus Infections.
- Donor selection in T-Cell replete haploidentical hematopoietic stem-Cell transplantation: knowns, unknowns and controversies.
- A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy.
- Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplant.
- Reply to sackstein.
- Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell...
- Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.
- Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside Analog-DNA alkylating agents in lymphoma cell lines.
- Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-Cell lymphoma: a phase 1/2 clinical trial.
- Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular Lymphoma: 12-year results.
- A foundation for "universal" T-Cell based immunotherapy: T-Cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous...
- Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Ty...
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
La Co Harbor UCLA Med Center
University Of California Los Angeles
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
UCLA Medical Center -
Harbor - UCLA Medical Center -
University of Chicago Pritzker School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1366541054 | |
| NPPES Provider LastName | CHAMPLIN | |
| NPPES Provider FirstName | RICHARD | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 679.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 32.0 | |
| Percent Opioid Claims | 4.71 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1366541054 |
| Last Name Of The Provider | CHAMPLIN |
| First Name Of The Provider | RICHARD |
| View All |
Similar Doctors
|
|
Dr. Sunil M. Patel, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark J. Routbort, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Muffaddal S. Morkas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francisco J. Esteva, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Gautam Borthakur, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael J. Overman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hartmut K. Koeppen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jun Zhang, MD |
|
|
Dr. Kurt Sizer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge E. Cortes-Franco, MD |
|
|
Dr. Emer Hanrahan, MD |
|
|
Dr. John T. French, MD |
|
|
Dr. An N. Hoang, MD |
|
|
Dr. Yan Zhou, MD
This Doctor is OpenDoctor Recommended.
|